Partner Headlines - ALKS

  1. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  2. Benzinga's Top Initiations

    Benzinga
  3. Barclays Initiates Alkermes With Overweight

    Benzinga
  4. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  5. Stocks Mostly Higher: Time Warner Clears Buy Point

    IBD
  6. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga
  7. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  8. Alkermes pops to 15-year high

    IBD
  9. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  10. Morning Market Gainers

    Benzinga
  11. Benzinga's Top #PreMarket Gainers

    Benzinga
  12. Benzinga's Volume Movers

    Benzinga
  13. 3 Biotech ETFs Rally On Merger News

    Benzinga
  14. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  15. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  16. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  17. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  18. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  19. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  20. Alkermes' drug passes trial

    IBD
  21. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  22. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  23. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  24. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  25. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  26. Benzinga's Volume Movers

    Benzinga
  27. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  28. Morning Market Movers

    Benzinga
  29. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  30. Benzinga's Top Initiations

    Benzinga
  31. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  32. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  33. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  34. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  35. Stocks End Short Week With Big Losses

    IBD
  36. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  37. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  38. Ireland Home To Several Fast Growing Health Care Names

    IBD
  39. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  40. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  41. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  42. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  43. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  44. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  45. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  46. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  47. Alkermes

    IBD
  48. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  49. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  50. Alkermes

    IBD
  51. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  52. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  53. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  54. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  55. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  56. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  57. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  58. Stocks Pare Early Losses, End With Modest Declines

    IBD
  59. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  60. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  61. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  62. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  63. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  64. Dow Leads Market Higher As Volume Swells

    IBD
  65. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  66. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  67. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  68. Stocks Tumble On Disappointing Earnings Reports

    IBD
  69. Why Cisco, Google And Apple All Became Big Winners

    IBD
  70. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  71. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  72. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  73. Alkermes Writes New Prescription For Growth

    IBD
  74. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  75. Health Care Sector Wrap

    FoxBusiness
  76. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  77. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  78. Elan

    IBD
  79. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  80. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  81. Market Roundup

    Benzinga
  82. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  83. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  84. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  85. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  86. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  87. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  88. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  89. Benzinga's Top Pre-Market Gainers

    Benzinga
  90. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  91. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  92. Benzinga's Volume Gainers

    Benzinga
  93. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  94. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
  95. Top-Performing Fund Managers Tap Retail, Food Stocks

    IBD
  96. Positive Data Lifts Stocks in Early Trading

    MarketIntelligenceCenter
  97. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
Trading Center